Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer

All-Comers Approach Disappoints

 
• By Andrew McConaghie

Metastatic prostate cancer continues to evade the checkpoint inhibitor class but Merck is not giving up on an area where overall survival remains limited.

Merck 1200
Merck and AstraZeneca's partnership has been successful but metastatic prostate cancer has again proven resistant to combination therapy • Source: Alamy

More from Anticancer

More from Therapy Areas